Caroline Charlier, Catherine Michaux
Lab. de Chimie Moléculaire Structurale, Facultés Universitaires N.-D. de la Paix, Rue de Bruxelles 61, B-5000, Namur, Belgium. caroline.charlier@fundp.ac.be
European journal of medicinal chemistry 2003 Jul-AugDual COX/5-LOX (cyclooxygenase/5-lipoxygenase) inhibitors constitute a valuable alternative to classical non-steroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors for the treatment of inflammatory diseases. Indeed, these latter present diverse side effects, which are reduced or absent in dual-acting agents. In this review, COX and 5-LOX pathways are first described in order to highlight the therapeutic interest of designing such compounds. Various structural families of dual inhibitors are illustrated.
Caroline Charlier, Catherine Michaux. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. European journal of medicinal chemistry. 2003 Jul-Aug;38(7-8):645-59
PMID: 12932896
View Full Text